S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
NASDAQ:IVVD

Invivyd (IVVD) Stock Price, News & Analysis

$2.30
-0.05 (-2.13%)
(As of 04/19/2024 ET)
Today's Range
$2.26
$2.45
50-Day Range
$2.30
$4.44
52-Week Range
$0.98
$5.20
Volume
1.06 million shs
Average Volume
1.23 million shs
Market Capitalization
$274.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.33

Invivyd MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
392.8% Upside
$11.33 Price Target
Short Interest
Healthy
3.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.09mentions of Invivyd in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.74) to ($0.14) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.72 out of 5 stars

Medical Sector

415th out of 909 stocks

Biological Products, Except Diagnostic Industry

62nd out of 151 stocks

IVVD stock logo

About Invivyd Stock (NASDAQ:IVVD)

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

IVVD Stock Price History

IVVD Stock News Headlines

Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Invivyd Appoints Jeremy Gowler As Interim CEO As Dave Hering Resigns
Invivyd Announces CEO Transition
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Invivyd: Q4 Earnings Insights
IVVD Stock Earnings: Invivyd Misses EPS for Q4 2023
Ligand Pharmaceuticals Incorporated
See More Headlines
Receive IVVD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/20/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IVVD
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.33
High Stock Price Target
$15.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+392.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-198,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.61 per share

Miscellaneous

Free Float
96,450,000
Market Cap
$274.21 million
Optionable
Optionable
Beta
0.63
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. David Hering M.B.A. (Age 48)
    CEO & Director
    Comp: $932.5k
  • Ms. Jill Andersen J.D. (Age 51)
    Chief Legal Officer & Corporate Secretary
    Comp: $619.33k
  • Mr. William E. Duke Jr. (Age 52)
    M.B.A., Chief Financial Officer
  • Mr. Jeremy Gowler (Age 47)
    Chief Operating Officer & Chief Commercial Officer
  • Ms. Stacy Price M.S. (Age 55)
    Chief Technology & Manufacturing Officer
  • Dr. Robert D. Allen Ph.D.
    Chief Scientific Officer

IVVD Stock Analysis - Frequently Asked Questions

Should I buy or sell Invivyd stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invivyd in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IVVD shares.
View IVVD analyst ratings
or view top-rated stocks.

What is Invivyd's stock price target for 2024?

3 analysts have issued twelve-month price objectives for Invivyd's stock. Their IVVD share price targets range from $9.00 to $15.00. On average, they expect the company's stock price to reach $11.33 in the next year. This suggests a possible upside of 392.8% from the stock's current price.
View analysts price targets for IVVD
or view top-rated stocks among Wall Street analysts.

How have IVVD shares performed in 2024?

Invivyd's stock was trading at $3.94 at the beginning of 2024. Since then, IVVD shares have decreased by 41.6% and is now trading at $2.30.
View the best growth stocks for 2024 here
.

Are investors shorting Invivyd?

Invivyd saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,320,000 shares, an increase of 41.5% from the March 15th total of 1,640,000 shares. Based on an average daily volume of 836,800 shares, the short-interest ratio is presently 2.8 days. Approximately 3.9% of the shares of the company are sold short.
View Invivyd's Short Interest
.

When is Invivyd's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our IVVD earnings forecast
.

What ETF holds Invivyd's stock?

Amplify Treatments, Testing and Advancements ETF holds 30,909 shares of IVVD stock, representing 0.32% of its portfolio.

How do I buy shares of Invivyd?

Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IVVD) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners